Moon T D, Vessella R L, Eickhoff M, Lange P H
Urology. 1983 Jul;22(1):16-9. doi: 10.1016/0090-4295(83)90337-0.
We compared a commercial radioimmunoassay kit with an enzymatic assay for prostatic acid phosphatase in monitoring the progression or remission of disease in 27 patients with prostatic cancer. In 5 of the 18 patients whose disease progressed, and in 4 of the 9 whose disease responded to treatment, the change was reflected better by the radioimmunoassay. In no case was the enzymatic assay better. Radioimmunoassay for prostatic acid phosphatase may be an effective and sensitive way to monitor the course of carcinoma of the prostate.
我们比较了一种市售的放射免疫分析试剂盒和一种前列腺酸性磷酸酶的酶促测定法，以监测27例前列腺癌患者疾病的进展或缓解情况。在疾病进展的18例患者中的5例，以及疾病对治疗有反应的9例患者中的4例，放射免疫分析能更好地反映变化。酶促测定法在任何情况下都没有更好。前列腺酸性磷酸酶的放射免疫分析可能是监测前列腺癌病程的一种有效且灵敏的方法。
